• Lee’s Pharmaceutical said China’s NMPA accepted its IND filing for proprietary ADC candidate ZK2401.
• Review is expected to take about 30 working days, with potential trial clearance as early as September 2026.
• First patient dosing could start as early as October 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lee's Pharmaceutical Holdings Limited published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260730-12262967), on July 30, 2026, and is solely responsible for the information contained therein.